论文部分内容阅读
背景与目的:化疗是晚期非小细胞肺癌(NSCLC)的主要治疗手段,但是NSCLC常对化疗耐药,导致治疗失败。因此,针对不同分子生物学特点的NSCLC进行化疗疗效预测,成为提高疗效的重要方法。本研究通过研究晚期NSCLC患者肿瘤组织中Stathmin基因的表达与患者对长春碱类药物的化疗敏感性的关系,为患者选择适当的药物治疗提供依据。方法:2005年5月—2007年12月,共78例晚期NSCLC患者入组,随机分入NP方案[长春瑞滨(NVB)联合顺铂(DDP)或卡铂(CBP)]化疗组或GP方案[吉西他滨(GEM)联合DDP或CBP]化疗组,观察两组对化疗的反应;同时以RT-PCR法检测患者病理组织中StathminmRNA的表达,以Western印迹法检测Stathmin的蛋白含量。结果:NP组41例,GP组37例,两组患者的性别、年龄、病理类型及肿瘤分期等临床特点无显著性差异(P>0.05),对化疗总的有效率分别为46.3%(19/41)和48.6%(18/37),两者之间亦未见显著差异(P>0.05);在NP组内,有效19例,无效22例,有效患者的肿瘤组织中stathminmRNA测量值为1.9±1.1,而无效患者为7.5±2.8,两者之间差异有显著性(P=0.003)。有效患者的Stathmin蛋白测量值为1.5±0.7,无效组为4.3±1.6,两者之间差异有显著性(P=0.002)。GP组18例有效,19例无效,有效与无效患者肿瘤组织中stathminmRNA及Stathmin蛋白无明显差异(P>0.05)。结论:NSCLC患者肿瘤组织中stathmin基因的表达与患者对长春碱药物的敏感性有关,stathmin基因高表达,对长春碱药物的敏感性低,宜换用其他药物治疗。
BACKGROUND & AIM: Chemotherapy is the primary treatment for advanced non-small cell lung cancer (NSCLC), but NSCLC is often resistant to chemotherapy and results in failure of treatment. Therefore, the prediction of chemotherapeutic effects on NSCLC with different molecular biological characteristics has become an important method to improve the curative effect. In this study, we investigated the relationship between Stathmin expression in patients with advanced non-small cell lung cancer (NSCLC) and chemosensitivity of vinca alkaloids in patients with advanced NSCLC, and provided the basis for selecting appropriate drug therapy. METHODS: From May 2005 to December 2007, a total of 78 patients with advanced NSCLC were enrolled and randomly assigned to NP regimen (NVB combined with cisplatin (DDP) or carboplatin (CBP)] or GP (Gemcitabine (GEM) combined with DDP or CBP] chemotherapy group, the response of the two groups to chemotherapy was observed. Stathmin mRNA expression was detected by RT-PCR and the protein content of Stathmin was detected by Western blotting. Results: There were 41 cases in NP group and 37 cases in GP group. There was no significant difference in gender, age, pathological type and tumor stage among the two groups (P> 0.05). The total effective rate of chemotherapy was 46.3% (19 / 41) and 48.6% (18/37), respectively. There was no significant difference between the two groups (P> 0.05). In the NP group, 19 cases were effective and 22 cases were ineffective. The stathminmRNA in the effective tumor tissue was 1.9 ± 1.1, but not effective in patients with 7.5 ± 2.8, the difference was significant (P = 0.003). The effective patient’s Stathmin protein measurement was 1.5 ± 0.7, the ineffective group was 4.3 ± 1.6, the difference was significant (P = 0.002). 18 cases were effective in GP group and 19 cases were ineffective. There was no significant difference in stathminmRNA and Stathmin protein between effective and ineffective patients (P> 0.05). Conclusion: The expression of stathmin in NSCLC patients is related to the sensitivity to vinblastine in patients with NSCLC. The stathmin gene is highly expressed, and its sensitivity to vinblastine is low.